Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients
NCT00382694Phase 2Unknown
- Sponsor
- Nordic Myeloma Study Group
- Start
- May 2005
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fludarabine in multiple myeloma (MM) (2 arms), sponsored by Nordic Myeloma Study Group. Primary endpoint: Toxicity and safety of Fludarabine by registration of side effects and adverse events (CTC). Status: unknown.
02
Drugs
fludarabine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00382694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00382694.